Those who develop cardiac hypertrophy at age 45 are able to achieve a life-span-neutral outcome if they are intervened early, but have a shorter survival period if they develop severe cardiac insufficiency. Myocardial hypertrophy refers to the thickening of the ventricular wall and falls under the category of ventricular remodeling, which is an inevitable process in the development and progression of heart failure. Myocardial hypertrophy is pathologically categorized as centripetal hypertrophy of the myocardium and belongs to the compensatory phase of heart failure. Application of drug therapy in myocardial hypertrophy can delay the development of heart failure to a certain extent, and generally does not affect life expectancy. Commonly used drugs include calcium channel blockers (e.g., nitrendipine, nifedipine, etc.) and angiotensin-converting enzyme inhibitors (e.g., captopril). If myocardial hypertrophy is not intervened, it may quickly progress to the end stage of heart failure, when the decline in cardiac function is obvious, and acute heart failure episodes may occur under the effect of certain triggers, then the survival rate is significantly reduced, and the survival period is very short. Therefore, myocardial hypertrophy at the age of 45 years needs to be actively treated to avoid the development of severe heart failure and to prolong survival.